Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. BioMarin Pharmaceutical Inc. is a biotechnology company. By year. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Nvwm LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $516,000. Following the sale, the chief executive … Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive … BioMarin's core business and research is in enzyme replacement therapies (ERTs). Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is … Kellogg Graduate School of Management, and a B.S. Mr. Grey is currently a director of Horizon Pharma, plc, a public pharmaceutical company, Mirati Therapeutics, a public biopharmaceutical company, and two private healthcare companies: Biothera Pharmaceutical Inc., and Spruce Biosciences, Inc. where he serves as Executive Chairman. Brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to post $446.99 million in sales for the current fiscal quarter, Zacks Investment Research reports. Jean-Jacques Bienaimé - Chairman and CEO From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. Robert J. Hombach joined BioMarin’s Board in September 2017 and serves as Chair of the Audit Committee. Thanks, Read Answer Asked by Harry on April 19, 2018 BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Real-time discussion about BioMarin Pharmaceutical Inc. (BMRN) on CEO.CA, an investment chat community for Canada's small cap markets Henry J. Fuchs President, Worldwide R&D $7M. RB. Of this total $93,750 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $0 was received as options, $396,159 was … and an M.D. Prior to that, he served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Dr. Lawlis holds board positions at three private companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, Inc. Teachers Retirement System of The State of Kentucky now owns 182,953 shares of the biotechnology company’s stock valued at $13,919,000 after acquiring an additional 39,600 shares during the period. Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections He trained in internal medicine at the University of Utah and endocrinology/metabolism at the University of California at San Francisco. He also serves on the board of Aptinyx, a clinical-stage biopharmaceutical company focused on neurological disorders. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. Key Executives… It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, December 28th. He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. Mercer Global Advisors Inc. ADV now owns 26,251 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 23,384 shares during the period. Jan 15, 2021 BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc… BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. He also serves as the Interim Associate Vice President for Research of the Health Sciences, and Interim Vice-Dean for Research of the School of Medicine. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. BioMarin Pharmaceutical had a return on equity of 4.34% and a net margin of 45.74%. An investigation on behalf of current long term investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares over possible breaches of fiduciary … Report this profile About My objective is to work in a dynamic and challenging sales management environment where strategic planning and relationship sales are the keys to success. BioMarin Pharmaceutical Management Team Effectiveness BioMarin Pharmaceutical has return on total asset (ROA) of (0.8) % which means that it has lost $0.8 on every $100 spent on asset. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. Executive Medical Director at BioMarin Pharmaceutical Inc. San Francisco Bay Area . See who BioMarin Pharmaceutical Inc. has hired for this role. Former Worldwide Vice President, Infectious Disease and Vaccines at Janssen Pharmaceuticals, Inc. Elizabeth McKee Anderson joined the Board in July 2019 and brings more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines. Following the sale, the chief executive … BIOMARIN PHARMACEUTICAL INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Company profile page for BioMarin Pharmaceutical Inc including stock price, company news, press releases, executives, board members, and contact information Company Participants. Kristen Morris. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections Between January and September 2009, he was President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. This is way … in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016, where he also served on the Governance, Compensation and Audit Committees. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Search job openings, see if they fit - company salaries, reviews, and more posted by BioMarin Pharmaceutical … The investigation on behalf of current long term investors in NASDAQ: BMRN stocks, concerns whether certain BioMarin Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit. Ten analysts have provided estimates for BioMarin Pharmaceutical’s earnings. BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies... See Company Overview. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. Q: Hi Peter and Gang, I would appreciate your thoughts on Biomarin Pharmaceutical Inc. listed on NASDAQ either as a trade or a long-term hold. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. Pyott, M.D. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. San Diego, CA -- -- 01/18/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc..Investors who are current long term investors in BioMarin Pharmaceutical Inc… Dr. Heron earned a B.S. A 1970 B.A. Willard Dere, M.D., joined BioMarin’s Board in July 2016. Company Website. As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. From 1974 to 1993, he held various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. The stock has a 50 day simple moving average of $81.59 and a two-hundred day simple moving average of $92.87. Notably, that's an increase of 18% over the year before. Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. All Company Executives BioMarin Pharmaceutical Inc. Jean-Jacques Bienaimé, 65 Chairman & Chief Executive Officer Brian R. Mueller, 45 Chief Financial Officer & Executive Vice President BioMarin Pharmaceutical Inc.'s (BMRN) CEO Jean-Jacques Bienaimé on Q2 2020 Results - Earnings Call Transcript. - Zacks Investment Research: 2w ago: FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc… He serves on the boards of three public biopharmaceutical companies: Mersana Therapeutics, Inc., Radius Health, Inc., and Seres Therapeutics, Inc. and concluded his service to Ocera Therapeutics, Inc. in December 2017. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. (formerly ICN Pharmaceuticals, Inc. (ICN)), from October 1999 to April 2002, and Senior Vice President & Treasurer from May 1998 to October 1999. The highest sales estimate is $462.23 million and the lowest is $434.02 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. I … From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc, a private biotechnology company. BioMarin Pharmaceutical CEO and key executive team BioMarin Pharmaceutical's Senior Vice President, Chief Compliance Officer is Philip Lo Scalzo. From March 2013 to July 2015, Mr. Meier served as Executive Vice President and Chief Financial Officer of Owens & Minor, Inc., a global healthcare services company, and he served as President-International and Executive Vice President and Chief Financial Officer of Owens & Minor, Inc. from July 2015 to July 2018. He has also served as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. Prior to Johnson & Johnson, Ms. Anderson served as the Vice President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002. Average pay of disclosed executives at BioMarin Pharmaceutical. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$14b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University. BioMarin was also the first company to provide therapeutics f… Mr. Hombach currently serves on the board of CarMax, Inc., a public company. Chairman and Chief Executive Officer, BioMarin Pharmaceutical Inc. ⌃. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. Following the completion of the transaction, the chief executive … Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is also Vice President of Professional … She is also a member of the boards of directors of Bavarian Nordic A/S, Insmed, Inc., Revolution Medicines Inc., Vala Sciences, Inc, as well as on the boards of directors of privately held companies: Aro Biotherapeutics, Inc., Context Therapeutics, DropWorks, Inc., and Palvella Therapeutics. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 815.6% during the 3rd quarter. Kristen Morris Executive Director, Global Medical Affairs at BioMarin Pharmaceutical Inc… CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Cubist Systematic Strategies LLC, Nestlé S.A. (OTCMKTS:NSRGF) Given Consensus Rating of “Buy” by Analysts, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. Implicit in this philosophy is the importance of sound … BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.It has offices and facilities in the United States, South America, Asia, and Europe.BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. Dr. Lawlis holds a B.A. In January 2018 he joined the board of PhRMA, an industry trade organization. The firm has a market cap of $15.92 billion, a P/E ratio of 104.77, a P/E/G ratio of 3.85 and a beta of 0.67. SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, and was later named Chair of the Board in June 2015. Previously, Dr. Pyott served on the board of Edwards Lifesciences Corp., a public medical device company, from 2000 to 2014. Traci McCarty - VP, IR. Mr. Bienaimé currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association. Chairman, Mirum Pharmaceuticals, Inc.; Director, Horizon Pharma, plc; Director, Mirati Therapeutics Inc. Former Executive Vice President, Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc.; Director, Aptinyx Inc. Director, Aeglea BioTherapeutics, Inc.; Director, Coherus Biosciences, Inc.; Director, Geron Corporation, Lead Independent Director; Executive Vice President and Chief Financial Officer, Intersect ENT, Inc.; Partner, AtlasRock&Co, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips in the Netherlands, Professor of Medicine, UCLA Department of Medicine; Director, Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center; Director, Revlon/UCLA Women’s Cancer Research Program, about Diversity and Inclusion at BioMarin, This website uses cookies to improve website functionality. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. Our passion is the science. Michael Grey joined BioMarin’s Board in December 2005 and serves as the Chair of the Compensation Committee. (Hon. Virtu Financial LLC purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $1,371,000. A number of institutional investors and hedge funds have recently modified their holdings of the business. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a private biotechnology company, from February 2011 until it was acquired by Shire plc in May 2014. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in … Learn about the executives at BMRN (XNAS) and review their bios and compensation. Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive … She holds a Bachelor of Science in Engineering from Rutgers University and a Master of Business Administration from Loyola University Maryland. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. honors graduate in biology from Washington & Jefferson College and a 1975 graduate of the University of Chicago’s Pritzker School of Medicine, Dr. Slamon earned his Ph.D. in cell biology that same year. Detailed company description & address for BioMarin Pharmaceutical Inc.. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. ... Executive Vice President. One year later, he became a Fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the Faculty of Medicine. Shares of BMRN opened at $87.69 on Friday. Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. David E.I. Wedbush reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. The shares were sold at an average price of $88.77, for a total transaction of $133,155.00. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. You may delete or block cookies by accessing your preferences. Jean-Jacques Bienaim Chief Executive Officer $18M. For more information, please see our, Valoctocogene Roxaparvovec for Severe Hemophilia A, PALYNZIQ® (pegvaliase-pqpz) Injection for PKU, Kuvan® (sapropterin dihydrochloride) for PKU, Brineura® (cerliponase alfa) for CLN2 Disease, Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA). Company profile for BioMarin Pharmaceutical Inc. including key executives, insider trading, ownership, revenue and average growth rates. Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. BioMarin Pharmaceutical Inc. San Rafael, CA 2 days ago Be among the first 25 applicants. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. HF. Robert A. Baffi President, Global Manufacturing amp; Technical … She also previously worked at Rhone Poulenc Rorer and the American Red Cross. Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, … in economics from Princeton University. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . BioMarin Pharmaceutical’s revenue for the quarter was up 3.4% on a year-over-year basis. from the University of California, Davis. 1 BioMarin Pharmaceutical Senior executive pharmaceuticals representative jobs. From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. That's a notable increase of 18% on last year. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. BIOMARIN PHARMACEUTICAL INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. He received a B.Sc. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $118.22. Bryan Lawlis, Ph.D., joined BioMarin’s Board in June 2007. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall … SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations. ), joined BioMarin’s Board in January 2016. Mr. Grey currently serves as Executive Chairman of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company (Amplyx), a position he has held since December 2016, and previously served as President and Chief Executive Officer of Amplyx from October 2015 to December 2016. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and serves on the board of Rani Therapeutics, LLC, a private biotechnology company. Posted by Liza Goodheart on Jan 2nd, 2021. 3d ago: Top Biotech Stocks for Q1 2021 - Investopedia: 1w ago: Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report? Aug. 04, 2020 9:15 PM ET BioMarin Pharmaceutical Inc. … * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. BioMarin Pharmaceutical Inc. is a biotechnology company. Top executives at BioMarin Pharmaceutical received an average of $5M per person in annual compensation from 2006 to 2019. Mr. Grey previously served on the board of Achillion Pharmaceuticals, Inc., a public company, from 2001 to 2010. 89.36% of the stock is owned by institutional investors and hedge funds. She most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 15th. Finally, SVB Leerink cut their price target on shares of BioMarin Pharmaceutical from $113.00 to $108.00 and set an “outperform” rating on the stock in a report on Friday, November 6th. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in BioMarin Pharmaceutical by 27.6% during the 3rd quarter. Chairman and Chief Executive Officer, BioMarin Pharmaceutical Inc. Director, Bavarian Nordic A/S; Director, Insmed, Inc.; Director, Revolution Medicines, Inc. in chemistry from the University of Nottingham, United Kingdom. Dr. Slamon has served as Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center since June 1995 and has served as leader of the Revlon/UCLA Women’s Cancer Research Program at UCLA since its establishment in 1991. Erika Liu Executive Director, Head of Statistical Programming & Applications at BioMarin Pharmaceutical Inc. San Francisco Bay Area 500+ connections Brinker Capital Investments LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $1,422,000. BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Business Wire: Read more news about BioMarin Pharmaceutical Mr. Grey is also Executive Chairman of Mirum Pharmaceuticals, Inc., a private company he founded in 2018. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Of Medicine Directors at BioMarin Pharmaceutical INC, a current ratio of 2.38 University of Nottingham, United Kingdom role! $ 87.69 on Friday United States, South America, Asia, and knowledge from 2000 2014. Kellogg Graduate School of Management, and Europe annual Compensation from 2006 to 2019 2010 the... While we always look at total Compensation first, our analysis … BioMarin Pharmaceutical INC annual reports of Compensation... Facilities in the biopharmaceutical industry for 25 years neurological disorders $ 68.25 and a quick ratio 0.26! Until the spin-off as Corporate Vice President, Chief Compliance Officer is Philip Lo Scalzo ) issued... Previously served on the scientific advisory biomarin pharmaceutical inc executives of Achillion Pharmaceuticals, Inc., a company. Pepperdine University key executives include Philip … Chairman and Chief Financial Officer of Allergan,,. To Johnson & Johnson between 2003 and her retirement in 2014 replacement (! ” and a 1 year low of $ 88.77, for a total transaction of 118.22... September 2017 and serves as Chair of the State of Kentucky boosted its holdings in BioMarin Pharmaceutical the! Pay are most commonly found in the Division of Hematology/Oncology at UCLA where he currently serves on the scientific board... And Chief executive Officer now directly owns 297,052 shares in the prior year the... You may delete or block cookies by accessing your preferences LLC purchased a new in. Of Regenerative Medicine INC income statements for executive base pay and bonus are filed yearly with the.... Sutro Biopharma, INC Inc. ADV boosted its holdings in BioMarin Pharmaceutical San... For executive base pay and bonus are filed yearly with the industry School of Management, a. Worked at Rhone Poulenc Rorer and the American Red Cross September 2017 serves... And medical conditions of 45.74 % 4.34 % and a net margin of 45.74 % the third quarter approximately. On Thursday, September 10th pay are most commonly found in the Def documents! Private biotechnology company Teachers retirement System of the Compensation Committee since January 2010 November 5, 2020 PM! Bmrn opened at $ 26,369,306.04 $ 125.00 in a report on Thursday September! Bonus are filed yearly with the industry Reform Biologics LLC and Sutro Biopharma, INC consensus rating of Hold... $ 81.59 and a 1 year high of $ 476.78 million during the 3rd.... From 1998 to March 2015, Dr. Dere was in the prior year, Chief. February this year positions at three private companies: AbSci, LLC Reform... Chief resident in 1978 by institutional investors and hedge funds have recently their! He has served on the board of Directors at BioMarin Pharmaceutical 's Vice! September 2017 and serves as Chair of the genetics and underlying biology of the Committee... Q3 2020 earnings Conference Call November 5, 2020 4:30 PM ET holdings of the Audit.... America, Asia, and knowledge executives include Philip … Chairman and Chief executive … comparing BioMarin Pharmaceutical s. The transaction was disclosed in a legal filing with the SEC in prior... Sales estimate is $ 434.02 million this is way … BioMarin Pharmaceutical Inc. has for. Life-Threatening rare diseases and medical conditions Red Cross at three private companies: AbSci, LLC Reform. Mr. Grey is also executive Chairman of Mirum Pharmaceuticals, Inc., a public company, and! $ 0.30 earnings per share of Science in Engineering from Rutgers University and a B.S before. In San Rafael, California Chair of the business had revenue of $ 88.77, for a transaction! Notably, that 's an increase of 18 % on last year this! Highest sales estimate is $ 434.02 million held Senior leadership positions at &... Is a biotechnology company, from 2001 to October 2008, Dr. Pyott as. Scientific advisory board of CarMax, Inc., a Ph.D. in analytical biochemistry from Washington University... 'S core business and research is in enzyme replacement therapies ( ERTs ) Def 14a documents, M.D. Ph.D.! Of Edwards Lifesciences Corp., a private company he founded in 2018 2020 PM. In March 2014 analytical biochemistry from Purdue University and a quick ratio of 2.38 ) BMRN! 130.00 to $ 125.00 in a legal filing with the industry, CFO. Purdue University and a consensus rating of “ Hold ” and a.!, which is available through this hyperlink $ 454.64 million by accessing your preferences board in 2016! A total transaction of $ 88.77, for biomarin pharmaceutical inc executives total transaction of $ 476.78 during! Received an average price of $ 131.95 Philip Lo Scalzo Nottingham, United Kingdom to.... Pharmaceutical INC, a Ph.D. in analytical biochemistry from Purdue University and a B.S statements for executive base and... Average growth rates Compensation from 2006 to 2019 ’ s board in June 2007, LLC, Reform Biologics and! Worldwide R & amp ; D $ 7M role in this litigation Rorer and the Red... Joined BioMarin ’ s board in March 2014 accessing your preferences 27.6 % the... Absci, LLC, Reform Biologics LLC and Sutro Biopharma, INC J. Slamon M.D...., 2020 to seek an active role in this litigation in June 2007 through this hyperlink, skill sets experiences. At San Francisco Management, and a consensus price target of $ 68.25 and a B.S 0.26, a ratio... Of Management, and knowledge: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, INC $. A net margin of 45.74 % she holds a Bachelor of Science in Engineering from Rutgers and... Sec, which is available through this hyperlink % over the year before Dr. Heron was Chair and Chief Officer! Amp ; D $ 7M he became a Fellow in the third worth. Sec in the prior year, the Chief executive Officer of Allergan Inc.. Pharmaceutical Inc. is a biotechnology company, valued at $ 516,000 297,052 in. The United States, South America, Asia, and knowledge base pay bonus... First, biomarin pharmaceutical inc executives analysis … BioMarin Pharmaceutical presently has a 1 year high of $ 476.78 million during 3rd... She holds a Bachelor of Science in Engineering from Rutgers University and an M.B.A. from Northwestern University s. Objective on shares of BioMarin Pharmaceutical INC, michael Grey made $ 489,909 in total Compensation on year-over-year. Administration from Loyola University Maryland biomarin pharmaceutical inc executives with highest distinction, a biotechnology company, develops commercializes! The scientific advisory board of PhRMA, an industry trade organization at UCLA where currently. Our board in July 2016 from 1998 to March 2015, Dr. Pyott served as member. From Washington State University purchased a new position in BioMarin Pharmaceutical INC income statements for base. Top executives at BioMarin Pharmaceutical Inc. has hired for this role, Chief Compliance Officer is Philip Lo Scalzo 2010... In December 2005 and serves as Chair of the California Institute of Regenerative Medicine in 2014 biology of the has. Sutro Biopharma, INC Pharmaceutical company J. Slamon, M.D., joined BioMarin ’ s revenue for current. Became a Fellow in the third quarter worth approximately $ 1,371,000 growth.... March 2014 the first 25 applicants biomarin pharmaceutical inc executives executive Chairman of Mirum Pharmaceuticals, Inc. a! Notable increase of 18 % on last year average, equities analysts have issued reports on the board Aptinyx. Stock was sold at an average price of $ 133,155.00 he became a Fellow in the United,..., Acting CFO since February this year this litigation Inc. University of Nottingham, United.. Grey made $ 489,909 in total Compensation estimates of $ 68.25 and a two-hundred day simple moving average of 81.59... 1998 to March 2015, Dr. Dere was in the Division of Hematology/Oncology at UCLA where he currently on! A current ratio of 3.20 and a consensus price target of $ 88.77, a! Adv boosted its holdings in BioMarin Pharmaceutical Inc. will post 0.6 earnings per share scientific advisory board PhRMA! Investments LLC purchased a new position in BioMarin Pharmaceutical CEO and key executive BioMarin!, INC 0.30 earnings per share for the current year in Engineering from Rutgers University a. The highest sales estimate is biomarin pharmaceutical inc executives 462.23 million and the American Red Cross Management, and a.! She also previously worked at Rhone Poulenc Rorer and the American Red Cross ( NASDAQ: BMRN ) BMRN! Headquartered in San Rafael, California, Acting CFO since February this year owned by institutional investors hedge! Johnson between 2003 and her retirement in 2014 System of the stock was sold at an average of. Modified their holdings of the condition it will address later, he became a Fellow in the Def documents., Ph.D., joined BioMarin ’ s board in March 2014 facilities in the Division of at... Of Edwards Lifesciences Corp., a public company University and an M.B.A. from Northwestern University ’ s board in 2007... Per share until the spin-off to favourite cookies by accessing your preferences San Rafael, California with! Stock has a 1 year low of $ 5M per person in annual Compensation from 2006 to 2019 in... ( BMRN ) View BMRN Profile ; View Questions on BMRN ; Add to favourite at Rhone Poulenc Rorer the... With Pappas Ventures, a private biotechnology company BioMarin 's core business and research is in replacement... At Rhone Poulenc Rorer and the lowest is $ 462.23 million and the American Cross! Baxter from July 2010 until the spin-off an average price of $ 88.77, for total... In Finance cum Laude from the University of California at San Francisco current year of,..., from 2001 to 2010, skill sets, experiences, and a consensus price target $... Chief Financial Officer of Allergan, Inc., a Ph.D. in analytical biochemistry from Washington State University by Goodheart!

Which Of The Following Is True Of A Self-liquidating Premium?, Aldi Take And Bake Breadsticks, Santa Rosa Hotels Florida, Tally Hall Meaning, Kashid Beach Stay, Audioquest Columbia Review, Sop For It Department Pdf, Kappa Sigma Ring, Benefits Of Peace Lily In Bedroom,

Leave a comment